RU2394580C2 - Способы лечения митохондриальных нарушений - Google Patents

Способы лечения митохондриальных нарушений Download PDF

Info

Publication number
RU2394580C2
RU2394580C2 RU2005121711/14A RU2005121711A RU2394580C2 RU 2394580 C2 RU2394580 C2 RU 2394580C2 RU 2005121711/14 A RU2005121711/14 A RU 2005121711/14A RU 2005121711 A RU2005121711 A RU 2005121711A RU 2394580 C2 RU2394580 C2 RU 2394580C2
Authority
RU
Russia
Prior art keywords
mitochondrial
syndrome
group
disorder
formula
Prior art date
Application number
RU2005121711/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2005121711A (ru
Inventor
Роберт К. НАВИОКС (US)
Роберт К. НАВИОКС
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Publication of RU2005121711A publication Critical patent/RU2005121711A/ru
Application granted granted Critical
Publication of RU2394580C2 publication Critical patent/RU2394580C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
RU2005121711/14A 1999-02-23 2000-02-23 Способы лечения митохондриальных нарушений RU2394580C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12158899P 1999-02-23 1999-02-23
US60/121,588 1999-02-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2001125913/14A Division RU2268732C2 (ru) 1999-02-23 2000-02-23 Способы лечения митохондриальных нарушений

Publications (2)

Publication Number Publication Date
RU2005121711A RU2005121711A (ru) 2007-01-20
RU2394580C2 true RU2394580C2 (ru) 2010-07-20

Family

ID=22397641

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005121711/14A RU2394580C2 (ru) 1999-02-23 2000-02-23 Способы лечения митохондриальных нарушений
RU2001125913/14A RU2268732C2 (ru) 1999-02-23 2000-02-23 Способы лечения митохондриальных нарушений

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2001125913/14A RU2268732C2 (ru) 1999-02-23 2000-02-23 Способы лечения митохондриальных нарушений

Country Status (20)

Country Link
US (2) US7638501B1 (https=)
EP (2) EP1808177B1 (https=)
JP (1) JP4776780B2 (https=)
KR (2) KR100758712B1 (https=)
CN (2) CN1191835C (https=)
AT (1) ATE381935T1 (https=)
AU (1) AU776437B2 (https=)
BR (1) BR0008447A (https=)
CA (1) CA2362925C (https=)
DE (1) DE60037578T2 (https=)
DK (1) DK1171137T3 (https=)
ES (1) ES2298130T3 (https=)
HU (1) HU230191B1 (https=)
IL (3) IL144964A0 (https=)
MX (1) MXPA01008549A (https=)
NZ (1) NZ513926A (https=)
PT (1) PT1171137E (https=)
RU (2) RU2394580C2 (https=)
WO (1) WO2000050043A1 (https=)
ZA (1) ZA200107727B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
EP2145627B1 (en) * 1998-07-31 2014-04-16 Massachusetts Institute Of Technology Use of uridine in combination with choline for the treatment of mood and emotional disorders
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
IL144964A0 (en) 1999-02-23 2002-06-30 Pro Neuron Inc Methods of treatment of mitochondrial disorders
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
DE10110355A1 (de) * 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
CA2444148A1 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
DE60213406T2 (de) * 2001-05-29 2007-03-08 The University Of British Columbia, Vancouver Pharmakologische anwendungen von mitochondriellen dna assays
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
NZ541306A (en) * 2003-01-17 2008-07-31 Cv Therapeutics Inc Substituted piperazine and piperidine derivatives useful in the treatment of cardiovascular diseases
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2622523C (en) * 2005-09-15 2014-02-18 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US8748405B2 (en) 2007-01-26 2014-06-10 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2009059306A1 (en) 2007-11-02 2009-05-07 Massachusetts Institute Of Technology Uridine dietary supplementation compliance methods and use thereof
CN101612110B (zh) * 2008-06-23 2012-07-25 欣凯医药化工中间体（上海）有限公司 三乙酰尿苷缓释制剂及其制备方法
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
RU2400221C2 (ru) * 2008-11-11 2010-09-27 ФГУ "Московский НИИ педиатрии и детской хирургии Росмедтехнологий" Способ лечения врожденных структурных миопатий и врожденных мышечных дистрофий путем коррекции вторичных митохондриальных изменений
ES2640485T3 (es) 2011-08-12 2017-11-03 Universitätsklinikum Freiburg Uridina y análogos de uridina para el uso en el tratamiento de la enfermedad pulmonar obstructiva crónica
WO2015106255A1 (en) 2014-01-13 2015-07-16 City Of Hope Multivalent oligonucleotide assemblies
WO2016028894A1 (en) * 2014-08-19 2016-02-25 Wellstat Therapeutics Corportion Treatment of glycosylation deficiency diseases
FR3027804A1 (fr) 2014-10-31 2016-05-06 Centre Nat Rech Scient Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives
US10675293B2 (en) 2015-05-29 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
BR112017025839A2 (en) * 2015-06-05 2018-08-14 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca treatment of mitochondrial diseases
JP6599484B2 (ja) * 2015-06-17 2019-10-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
KR101981843B1 (ko) 2016-09-13 2019-05-23 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 미토콘드리아 기능 개선용 조성물
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
US20230000894A1 (en) * 2019-09-05 2023-01-05 Mitorainbow Therapeutics, Inc. Treating mitochondrial dna depletion disorders
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
KR102290596B1 (ko) 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도
EP4210709B1 (en) * 2020-09-14 2025-10-29 Pharma Cinq, LLC 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
EP3970713A1 (en) 2020-09-16 2022-03-23 GV Squared S.r.l. Pharmaceutical composition comprising uridine and pyruvate for regulating the profileration, activity and survival of immune cells
BR112023010517A2 (pt) * 2020-12-01 2024-02-06 Wellstat Therapeutics Corp 5'-o-fenilacetil uridina e seu uso terapêutico
CN113116900B (zh) * 2021-04-14 2022-07-08 兰州大学 一类核苷类似物在制备预防和/或治疗脑血管疾病药物中的应用
BE1030026B1 (fr) * 2022-06-14 2023-07-07 Dendrogenix Composés dérivés de stérols et composition pharmaceutique les comprenant pour leur utilisation dans la prévention, l’amélioration et/ou le traitement d’une pathologie liée à un déficit mitochondrial

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2077883C1 (ru) * 1988-12-22 1997-04-27 Христиан Скрецек Композиция для внутривенного введения для защиты почек от токсического действия нефротоксичных цитостатических средств и иммуносупрессоров
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
JPS5356690A (en) * 1976-09-30 1978-05-23 Rikagaku Kenkyusho Purin compund sugar derivatives and their preparation
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US6329350B1 (en) 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
JP2894610B2 (ja) * 1987-10-28 1999-05-24 プロ−ニューロン，インコーポレーテッド アシル化ウリジンおよびシチジンならびにその使用
DE3856557T2 (de) 1987-10-28 2004-06-03 Wellstat Therapeutics Corp. Acyldeoxyribonukleosid-Derivate und Verwendungen davon
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6348451B1 (en) 1987-10-28 2002-02-19 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US7307166B1 (en) 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IT1241984B (it) 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
ATE271614T1 (de) * 1992-05-28 2004-08-15 Ct For Molecular Biology And M Quinone-derivate zur verbesserung der zellulare bioenergie
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5852000A (en) 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
CN1150433A (zh) * 1994-03-30 1997-05-21 米托科公司 线粒体缺陷相关疾病的诊断，治疗以及细胞和动物模型
JP3808121B2 (ja) * 1995-01-09 2006-08-09 日本メジフィジックス株式会社 低酸素症またはミトコンドリア機能障害診断剤
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
JPH10273469A (ja) * 1997-02-03 1998-10-13 Takeda Chem Ind Ltd ２環性キノン誘導体、製造法および剤
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
IL144964A0 (en) 1999-02-23 2002-06-30 Pro Neuron Inc Methods of treatment of mitochondrial disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
RU2077883C1 (ru) * 1988-12-22 1997-04-27 Христиан Скрецек Композиция для внутривенного введения для защиты почек от токсического действия нефротоксичных цитостатических средств и иммуносупрессоров

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ЗАПРУДНОВ A.M. Синдром Рея в детском возрасте. - М., 1997, с.8-27. TANAKA J et al. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome С and vitamins B1 and B2 // Brain Dev. 1997 Jun; 19(4):262-7. реферат, он-лайн [Найдено в Интернет на www.pubmed.com 22.12.2008], PMID: 9187476 [PubMed - indexed for MEDLINE] 22.12.2008. TAYLOR RW et al. Treatment of mitochondrial disease // J Bioenerg Biomembr. 1997 Apr; 29(2):195-205 реферат, он-лайн [Найдено в Интернет на www.pubmed.com], PMID: 9239544 [PubMed - indexed for MEDLINE] 22.12.2008. *
МАРИ Р. и др. Биохимия человека. - М.: Мир, 1993, т.2, с.31-33. *

Also Published As

Publication number Publication date
US7638501B1 (en) 2009-12-29
IL180528A0 (en) 2007-06-03
IL144964A (en) 2013-11-28
RU2005121711A (ru) 2007-01-20
AU2004235661A1 (en) 2005-01-27
JP2002537340A (ja) 2002-11-05
DE60037578D1 (de) 2008-02-07
IL180528A (en) 2013-11-28
CN1626107A (zh) 2005-06-15
MXPA01008549A (es) 2003-06-06
WO2000050043A1 (en) 2000-08-31
EP1171137A4 (en) 2004-04-07
CN1191835C (zh) 2005-03-09
CN100379426C (zh) 2008-04-09
RU2001125913A (ru) 2005-02-20
HUP0400914A3 (en) 2007-05-29
KR20020031331A (ko) 2002-05-01
EP1808177B1 (en) 2018-08-08
NZ513926A (en) 2001-09-28
PT1171137E (pt) 2008-03-17
ZA200107727B (en) 2007-10-31
ES2298130T3 (es) 2008-05-16
EP1808177A2 (en) 2007-07-18
CA2362925C (en) 2011-04-12
EP1171137A1 (en) 2002-01-16
US20100098678A1 (en) 2010-04-22
HUP0400914A2 (hu) 2004-08-30
CA2362925A1 (en) 2000-08-31
JP4776780B2 (ja) 2011-09-21
IL144964A0 (en) 2002-06-30
RU2268732C2 (ru) 2006-01-27
CN1341024A (zh) 2002-03-20
DE60037578T2 (de) 2009-01-08
US8748408B2 (en) 2014-06-10
KR20070085864A (ko) 2007-08-27
BR0008447A (pt) 2002-01-15
AU3243400A (en) 2000-09-14
KR100879559B1 (ko) 2009-01-22
DK1171137T3 (da) 2008-03-31
EP1171137B1 (en) 2007-12-26
ATE381935T1 (de) 2008-01-15
KR100758712B1 (ko) 2007-09-14
HU230191B1 (hu) 2015-09-28
EP1808177A3 (en) 2010-07-28
AU776437B2 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
RU2394580C2 (ru) Способы лечения митохондриальных нарушений
US20020035086A1 (en) Acylated uridine and cytidine and uses thereof
HK1005740A1 (en) Acylated uridine and cytidine and uses thereof
KR20120115344A (ko) 안압을 감소시키는 혼합물, 키트 및 방법
EP1365755B1 (de) Die verwendung von pyrimidinnukleosiden und/oder prodrugs davon zur bekämpfung von nebenwirkungen der "haart" (highly active anti-retroviral therapy) und anderen antiviralen therapien
US20040224920A1 (en) Methods of treatment of mitochondrial disorders
WO2021047525A1 (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
US5700803A (en) Method for reducing infarct size in subjects afflicted with ischemic heart disease
EP4487698A1 (en) A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
JP5366386B2 (ja) 神経細胞賦活及び神経伸長促進用組成物
JP2025524861A (ja) ウリジントリアセテート非晶質製剤およびその使用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180224